Cariporide

Cariporide

Cariporide is a selective sodium-hydrogen antiporter 1 (NHE-1) inhibitor that was developed by Sanofi-Aventis. It is primarily used in the treatment of ischemic heart disease, specifically to reduce the risk of myocardial infarction (heart attack).

Mechanism of Action

Cariporide works by inhibiting the NHE-1 antiporter, a protein that regulates the balance of sodium and hydrogen ions in cells. This inhibition reduces the amount of sodium and calcium that enters the cell during ischemic conditions, which can help to prevent cell death and reduce the size of a myocardial infarction.

Clinical Trials

Cariporide has been studied in several large-scale clinical trials. The most notable of these was the Guardian trial, which evaluated the efficacy of cariporide in reducing the risk of death and myocardial infarction in patients undergoing coronary artery bypass graft (CABG) surgery. The results of this trial were promising, but the drug has not yet been approved for this use by the Food and Drug Administration (FDA).

Side Effects

Like all medications, cariporide can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, and hypotension (low blood pressure). In rare cases, cariporide can cause serious side effects such as arrhythmia (irregular heartbeat) and hyperkalemia (high potassium levels in the blood).

Future Research

While cariporide is not currently approved for use in the United States, research into its potential benefits continues. Future studies may focus on its potential use in other conditions, such as stroke and chronic heart failure.

This pharmacology related article is a stub. You can help WikiMD by expanding it.